Sodium-glucose cotransporter-2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis.

Front Pharmacol · 2023 · PMC10657831 · PMID 38027019

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

slightly significantno p-value reported

For fractures, canagliflozin showed a slightly significant increased reporting when compared with DPP4 inhibitors (not confirmed in the sensitivity analysis), whereas all other comparison showed no statistically significant difference.

also in 1,750 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.